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Thirty-five Franklin Size
Double Lumen Tube May
Not Be Suitable for
Tall Patients
To the Editor:
A recent study by Amar et al.
concluded that the use of smaller
than conventionally sized double
lumen tubes (DLTs) was not associ-
ated with any differences in clinical
intraoperative outcomes including
transient hypoxemia. However, the
authors used DLTs from one manu-
facturer (Sheridan, Telefex Medical,
Research Triangle Park, NC).1 Par-
tridge et al. have shown that same
size DLTs from different manufac-
turers have different margins of
safety 2,3 with tubes manufactured
by Sheridan having a greater margin
of safety compared to those from
other manufacturers.
Thus, we suggest that extrapolat-
ing these results to DLTs other than
those manufactured by Sheridan
may result in more episodes of
intraoperative tube malposition
and hypoxemia. Although the ready
availability of fiberoptic brocho-
scope to adjust for DLT displace-
ment or malposition during surgery
is considered routine care, too fre-
quent adjustments by the fiberoptic
brochoscope intraoperatively could
be both cumbersome and may not be
possible in all cases.
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In Response:
Although we agree that the paper
by Partridge and Russell1 points to
inter- and intramanufacturer vari-
ability of double lumen tubes (DLT)
cuff to tip distances, they also did not
provide any statistical comparisons
between the sizes among the manu-
facturers to substantiate that smaller
DLT by Sheridan are safer. Thus, and
as pointed out by Punj et al.2 our
conclusions were based on use of
DLT from a single manufacturer. In
addition, and as stated in our paper,
we view fiberoptic confirmation and
intermittent verification of DLT
position regardless of manufac-
turer as an integral part of the
anesthetic management.
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Intraarticular Tramadol or
“Hot Chili Peppers”?
To the Editor:
Fans of tramadol should thank
Zeidan et al. for their recent report,1
showing that tramadol 100 mg,
used as an adjuvant to bupivacaine
and injected intraarticularly, pro-
vides extended analgesia after
arthroscopic knee surgery. Our
concern is, however, the safety of
tramadol administration into the
knee joint. It has been found that
tramadol can lead to local release of
various peptides that act on neigh-
boring tissues, producing vasodila-
tion, immunomodulation, cytokine
and mediator release.2 These effects
have been attributed to activation
of the transient receptor potential
vanilloid-1 (“the capsaicin recep-
tor”), which can also be activated
by hot chili peppers2 and is sup-
ported by human studies, showing
that local tramadol, can result in
skin erythema, flare, and urticaria,
and initiate burning skin sensa-
tion.3,4 It is conceivable, therefore,
that if tramadol, applied locally,
can cause such on-site responses,
then it may also produce similar
effects in the knee, which leads us
to question the safety of intraartic-
ular tramadol injection.
In our opinion, tramadol, resem-
bling “hot chili peppers” in action,
should be proven devoid of unto-
ward effects on the knee, before the
practice of intraarticular tramadol
is considered safe.
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In Response:
We agree with Dr. Tabboush that
the mentioned side effects are well
known.1 We also are aware of the
recent study from Marincsak et al.2
and acknowledge this work for of-
fering a better understanding of the
side effects and/or mechanism of
action of tramadol. However, we
believe that one should differenti-
ate between the onset of side effects
and its correlation with and ex-
trapolation to overall safety. Our
study focused on side effects and
our data showed no side effects of
intra-articular (IA) tramadol 100
mg during the first 24 hr postopera-
tively.3 We are convinced that our
investigation could be done safely
as several studies showed that IA
tramadol can be used safely dur-
ing arthroscopic surgery.4 – 6 Addi-
tionally, Garlicki et al.7 showed
that tramadol inhibits nociception
and edema after its local applica-
tion directly to the inflamed knee
joint, which is in contrast with the
reports mentioned by Dr. Tab-
boush. Finally, although effects of
local application of tramadol have
been described, many years of
clinical use suggest that tramadol
can be used intramuscularly and
subcutaneously without signifi-
cant major side effects. However,
because IA administration of tra-
madol still has to be considered
an experimental application, we
agree that more research is re-
quired to prove and support the
safety of its IA administration.
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Coagulation Monitoring
To the Editor:
Viscoelastic coagulation tests are
used to manage perioperative co-
agulation disorders, and we believe
that a recent article by Ganter and
Hofer1 contains a misleading leg-
end probably reflecting a misun-
derstanding of the concept of the
Sonoclot device. In Figure 3B ex-
plaining the Sonoclot device, plate-
let function (PF) was defined as the
time from beginning of the Sonoclot
measurement until the peak of the
curve. However, the function of the
platelets is reflected by both the rate
of clot formation (steepness of the
curve) as well as the retraction of
the clot, represented by the follow-
ing Sonoclot signature after the
peak.2 The downward slope after
the peak is produced as platelets
further contract the clot. Both the
number of available platelets and
the level of PF are key determinants
of the downward slope. The peak
itself is a composite measurement
of the fibrinogen and the interaction
of platelets with the coagulatory cas-
cade. Finally, also included in the PF
time is activated clotting time. This
value is obviously influenced by hep-
arin, but not by platelets.
Guido Schu¨pfer, MD, PhD
Mattias Casutt, MD
Institute of Anesthesiology and Intensive Care
Kantonsspital, Spitalstrasse, Switzerland
mattias.casutt@ksl.ch
REFERENCES
1. Ganter MT, Hofer CK. Coagulation Moni-
toring: Current techniques and clinical use
of viscoelastic point-of-care coagulation de-
vices. Anesth Analg 2008;108:1366–75
2. Hett DA, Walker D, Pilkington SN, Smith
DC. Sonoclot Analysis. Br J Anaesth 1995;
75:771–6
DOI: 10.1213/ane.0b013e31818a0de0
In Response:
Casutt and Schu¨pfer1 commented
on the concept of the platelet func-
tion (PF) measured by the Sonoclot
Analyzer (Sonoclot Coagulation &
Platelet Function Analyzer, Sienco,
Arvada, CO). Figure 3B in our ar-
ticle2 presented an initial character-
ization of the Sonoclot Signature
and attempted to illustrate that
there is both a time component re-
lated to platelet activation as well
as a clot retraction quality compo-
nent. Although the graph only in-
troduced the concept of PF, the text
clearly states that PF as reported on
the Sonoclot Analyzer is “derived
from the timing and quality of the
clot retraction.” The actual algo-
rithm for the numerical PF result
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